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Mitochondrial preparations, obtained from human tonsils and from rat spleen, liver, heart, and kidney 
tissues, bound [lzsI]Clq with affinities of 10210” M-l. The binding of Clq was not affected by treatment 
of the mitochondrial preparations with pronase, trypsin, or phospholipase D, but it was lowered S-&fold 
following treatment ofthe mitochondria with DNase and RNase. Binding of Clq to mitochondrial prepara- 
tions was also greatly diminished by limited chemical modi~cation of Clq with cyclohexane-l,Z-dione. It 
is suggested that the reported binding of Clq to mitochondria may have arisen from the protein binding 
to DNA and/or RNA contaminating the mitochondrial preparations. 
Clq Mitochondria Nucleic acid 
1. INTRODUCTION 
The classical pathway of complement activation 
is triggered by the interaction of the first comple- 
ment component (Cl) with aggregates of IgG or 
IgM [ 11. This activation leads to the generation of 
several biological activities that initiate inflamma- 
tion and facilitate interactions with various effec- 
tor cells. A substantial number of membrane 
preparations have been shown to bind CI, with the 
resultant activation of the classical pathway, in the 
absence of specific antibodies [2-41. In these cases, 
interaction with subcomponent Clq has been 
demonstrated, implying that complement is ac- 
tivated by a mechanism similar to that of IgG im- 
mune complexes. 
Antibody-independent activation of Cl in serum 
following exposure to isolated human heart mito- 
chondrial membranes in vitro has also been re- 
ported [5-91, leading to the hypothesis that the 
release of mitochondrial membranes of portions 
thereof from traumatized cardiac cells following 
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Nuclease Cyclohexane-I ,bdione 
an acute myocardial infarction, can lead to a direct 
antibody-independent activation of the comple- 
ment system, resulting in the initiation of an in- 
flammatory reaction at the site of tissue damage 
181. 
Below we present evidence that the complement 
activation by mitochondrial preparations may be 
caused by contaminating DNA and/or RNA. In- 
teraction of Clq with DNA, leading to complement 
activation, has already been established [lo], but 
the possibility that this is the cause of the observed 
binding of Clq to mitochondrial preparations has 
not been previously examined. 
2. MATERIALS AND METHODS 
Bovine serum albumin (BSA), polyethylene 
glycol (&& 8000, PEG), ribonuclease A (EC 
3.1.27.5) and deoxyribonuclease I (EC 3.1.21.1) 
from bovine pancreas, trypsin (EC 3.4.21.4), pro- 
nase E, and phospholipase D (EC 3.1.4.4) were 
from Sigma. Cyclohexane-1,2-dione was from 
Pierce, Rockford, USA. Human Clq was isolated 
from human serum and labelled with lz51 using lac- 
toperoxidase [ 111. Human mitochondria were 
prepared from tonsils removed from patients of 
Petersham Private Hospital, Sydney, Australia, 
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washed immediately with 0.25 M sucrose in 0.01 M (w/w) protein) [‘*‘I]Clq (0.039 mg/ml) was then 
Tris (pH 7.3) and stored at 4°C until processed added quickly followed by ice-cold PEG (2.8%, 
(usually less than 24 h). w/v) in a total volume of 0.4 ml. 
2.1. Mitochondrial preparations 
Human and rat tissues were trimmed, suspended 
in 0.25 M sucrose in 0.01 M Tris (pH 7.3) and 
homogenized for 10 s at 4°C. The crude homo- 
genate was centrifuged at 8OOxg for 10 min and 
the supernatant recentrifuged at 1OOOOxg for 30 
min at 4°C. The mitochondrial pellet was resus- 
pended in the same buffer and recentrifuged 
before being divided into aliquots and stored at 
- 70°C. Mitochondrial ‘ghost’ membranes were 
prepared by suspending thawed mitochondria in 
distilled water 3 times; the membranes were col- 
lected by centrifuging (lOOOOxg, 5 min, 4°C). 
3. RESULTS AND DISCUSSION 
A number of reports [5-91 have convincingly 
demonstrated that cellular and subcellular mem- 
branes obtained from various sources can bind and 
activate the first component of complement Cl; 
Storrs et al. [6] also showed that Cl interacted with 
membrane binding sites through the globular head 
regions of subcomponent Clq. 
2.2. C@ binding assay 
The binding of Clq to mitochondrial membranes 
was determined by incubation of ‘251-labelled Clq 
(O-0.04 mg/ml, 6.2x lo6 cpm/mg) with a mito- 
chondrial suspension (typically 0.09 mg/ml pro- 
tein) in 0.01 M phosphate, 0.12 M NaCl, 0.5% 
(w/v) BSA, pH 7.2 for 1 h at 37’C. Ice-cold PEG 
was quickly added to the mixture to give a final 
concentration of 2.8% (w/v) and the tubes in- 
cubated on ice for 1 h. The insoluble Clq-mem- 
brane complexes were collected by centrifuging 
(10~0 xg, 5 min, 4°C) and the radioactivity 
associated with the pellet and the supernatant 
determined. 
We also have obtained high affinity binding of 
Clq to mitochondrial preparations from human 
tonsils and from rat spleen, liver, heart, and 
kidney tissues. As observed previously with mito- 
chondrial membranes from other species [5,6], the 
Scatchard plots of the binding data were biphasic 
(fig,l) suggesting the presence of at least two 
classes of Clq binding sites in the mitochondrial 
preparations. 
Linear regression analysis of the two linear sec- 
tions of the Scatchard plots gave the results shown 
in table 1. No significant difference in the affinity 
of Clq for the mitochondrial membranes of dif- 
ferent tissues was observed, but human mitochon- 
drial preparations were able to bind more Clq than 
rat preparations. 
2.3. Modification of arginyl residues 
Clq (0.17 mg/ml, 6.2 x lo6 cpm/mg) in 0.025 M 
borate, 0.5010 (w/v) BSA, pH 9.0, was incubated 
for 30 min at 37°C in the presence of 0.025 M 
cyclohexane-1,2-dione. The solution was the ad- 
justed to 0.05 M in arginine and the protein 
chromatographed over Sephadex G-50, equilibrated 
with 0.02 M borate, 0.15 M NaCI, 0.570 (w/v) 
BSA, pH 7.2. 
2.4. Enzymatic digestions 
Aliquots of the mitochondrial preparations 
(typically containing 0.04 mg protein) were in- 
cubated with the appropriate enzyme in a total 
volume of 0.2 ml at 37°C for 1 h; trypsin digestion 
(1% w/w protein) was performed for 10 min and 
the reaction stopped with trypsin inhibitor (2% 
Enzymatic treatment of human mitochondria 
with pronase, trypsin, or phospholipase D did not 
affect their Clq binding activity (table 2). These 
results suggest hat the Clq binding activity is prob- 
ably not associated with a membrane surface pro- 
tein or with the charged moieties of the membrane 
phospholipids. However, treatment of the prepa- 
rations with nucleases resulted in a substantial 
decrease in their Clq binding activity (table 3), im- 
plicating contaminating nucleic acids as the Clq 
receptors. Lysed mitochondria, as well as the 
~ytoplasmi~ fraction obtained during the prepara- 
tion of the organelles, were also able to bind Clq 
and the Clq binding activity of these fractions was 
also reduced by the nuclease digestions. The bind- 
ing was reduced after 3 washings of the control- 
ysed mitochondria (‘ghost membranes’), support- 
ing the idea that a contaminant associated with the 
mitochondria was responsible for the binding. 
Chemical modification of Clq with the arginine- 
specific reagent cyclohexane-1,2-dione decreased 
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Fig.1. Binding of human Clq to mitochondrial 
preparations from human tonsils (a) and rat spleen (b). 
The concentration of ‘251-labelIed Clq bound to the 
organelles (0.2 mg protein/ml) was determined, as in 
section 2, with an input ‘251-labelled Ciq concentration 
range of O-0.04 mg/ml (6.2 x lo6 cpm/mg). 
Table 1 
Kinetic analysis of Clq binding to mitochondrial 
preparations from human and rat tissues 
Tissue Capacity 
(nmol/mg 
protein) 
Affinity 
constants 
(x108 M-Q 
Human tonsils 0.36 2.63 
0.20 0.77 
Rat spleen 0.16 3.07 
0.19 0.61 
Rat kidney 0.06 3.21 
0.10 0.64 
Rat heart 0.10 3.33 
0.14 0.58 
Rat liver 0.08 3.10 
0.12 0.70 
Clq (O-0.04 mg/ml) and the mitochondrial suspensions 
(0.09 mg protein/ml) were incubated as in section 2 and 
the results were analysed by linear regression analysis of 
the two linear sections of the Scatchard plots obtained to 
give the extrapoiated amount of Clq bound at saturating 
Clq concentrations (capacity) and the apparent affinity 
constants for the interactions 
Table 2 
The effect of the enzymatic treatment of mitochondria 
and of the chemical modification of Clq on the binding 
of Clq to the organelles 
Treatment Binding (%I 
Mitochondria 
Control 
Pronase 
Trypsin 
Phospholipase D 
100.0 
99.7 
100.8 
99.2 
w 
Control 100.0 
Cyclohexane-1 ,Zdione 32.9 
Human mitochondrial preparations were incubated with 
the appropriate enzyme and Clq was modified with 
cyclohexane-1,2-dione as described in section 2. The 
binding of Clq (0.039 mglml) to the mitochondrial 
preparations (0.04 mg protein) is expressed as a 
percentage of that to untreated control preparations 
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Table 3 
The effect of nuclease digestion of the mitochondrial preparations on their Clq binding activity 
Binding (%) 
Preparation Human tonsils Rat spleen 
Control Digested Control Digested 
Mitochondrial fraction 69.9 12.2 67.1 11.7 
Cytoplasmic fraction 77.1 8.5 70.6 4.6 
Lysed mitochondria 74.6 14.3 70.9 5.3 
Mitochondrial ‘ghosts’ 40.2 13.3 39.5 10.9 
An aliquot of each preparation (0.04 mg protein) was incubated with DNase (0.006 mg) and RNase 
(0.03 mg) in a total volume of 0.2 ml of 0.01 M phosphate, 0.15 M NaCl and 0.5% (w/v) BSA, 
pH 7.2 at 37°C for 1 h. [‘*51]Clq (0.016 mglml) and ice-cold PEG (2.8%, w/v) were then added 
and incubation continued on ice for I h. The ‘251-labelled Clq bound to membranes was determined 
as in section 2, and is expressed as a percentage of the input ‘251-labelled Clq 
the binding to l/3 that of a control sample. 
Chemical modification of about 37 arginyl residues 
of Clq has been reported to abolish 8.5% of the 
DNA-precipitating activity of Clq [lo]. 
Our results would then suggest that the observed 
binding of Clq to mitochondria and the subsequent 
complement activation may be due to Clq binding 
to nucieic acids contaminating the preparations. 
We suggest that results of Clq binding to mito- 
chondria should be treated with caution pending 
an assessment of the extent of nucleic acid con- 
tamination of the preparations. 
A physiological role for the antibody-inde- 
pendent activation of complement by several mem- 
brane preparations has been suggested [6]; such 
membranes, normally localized within the bound- 
ary of the plasma membrane, are exposed to 
plasma Clq after tissue injury. Binding and com- 
plement activation would then lead to acute in- 
flammation through the complement anaphylatox- 
ins, chemotactic peptides and opsonins. It is rele- 
vant to note that the suggested physiological role 
for the antibody-independent activation would still 
be valid if Clq binds to nucleic acid, which is 
always released after tissue injury. 
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